利拉鲁肽联合二甲双胍治疗初发肥胖2型糖尿病的临床观察

Clinical observation of liraglutide combined with metformin in the treatment of newly diagnosed obese type 2 diabetes

目的探讨利拉鲁肽联合二甲双胍治疗初发肥胖2型糖尿病的临床观察。方法选取2017年2月~2019年2月我院收治的初发肥胖2型糖尿病患者84例,随机分成研究组和对照组各42例,对照组给予二甲双胍治疗,研究组给予利拉鲁肽联合二甲双胍治疗。观察分析两组疗效、不良反应以及血糖水平等。结果研究组临床疗效高于对照组,差异有统计学意义(P<0.05);研究组FBG、2hBG、HbAlC、BMI以及HOMA-IR等指标改善水平高于对照组,差异有统计学意义(P<0.05);研究组不良反应发生率低于对照组,差异有统计学意义(P<0.05)。结论对初发肥胖2型糖尿病患者应用利拉鲁肽联合二甲双胍治疗效果理想,可有效提高胰岛素功能,进而改善患者血糖以及血脂水平,降低不良反应对患者的影响,有利于进一步增强治疗疗效,可推广使用。

Objective To explore the effect of liraglutide combined with metformin in the treatment of newly diagnosed obese type 2 diabetes.Methods A total of 84 patients with newly diagnosed obese type 2 diabetes admitted to our hospital from February 2017 to February 2019 were randomly divided into the study group and the control group,with 42 patients in each group.The control group was treated with metformin,and the study group was treated with liraglutide combined with metformin.The efficacy,adverse reactions and blood glucose levels of the two groups were observed and analyzed.Results The clinical efficacy of the study group was higher than that of the control group,and the difference was statistically significant(P<0.05).The improvement of fasting blood glucose(FBG),2 hours blood glucose(2hBG),hemoglobin Alc(HbAlC),body mass index(BMI),and homeostasis model assessment of insulin resistance(HOMA-IR)in the study group were higher than those in the control group,and the differences were statistically significant(P<0.05).The incidence of adverse reactions in the study group was lower than that in the control group,and the difference was statistically significant(P<0.05).Conclusion The application of liraglutide combined with metformin in patients with newly diagnosed obese type 2 diabetes is ideal,which can effectively improve insulin function,improve the blood glucose and blood lipid levels of patients,reduce the adverse effects on patients,and further help enhance the therapeutic effect.It is worthy of promotion.